pharmaphorum

AUGUST 31, 2021

Just a few months after breaking cover with its new take on RNA therapeutics, Laronde has raised an impressive $440 million in second-round financing backed by Flagship Pioneering – which was behind the founding of mRNA specialist Moderna. The company has an ambitious goal of producing 100 eRNA medicines in the next decade.

RNA 52

RNA Protein Immune Response Medicine 52

Pharmaceutical Technology

APRIL 20, 2023

Targovax has unveiled plans to rebrand as Circio , reflecting its strategic shift to focus on expediting the development of its innovative circular RNA (circRNA) platform. Initially reported in 2011, CircRNA is a naturally occurring class of RNA.

Gene Therapy 240

Gene Therapy RNA Gene Engineer 240

Drug Discovery World

OCTOBER 5, 2023

Join DDW’s Megan Thomas and Reece Armstrong with sponsors Taconic for the first DDW Turning Science into Business Summit, ‘ Cancer research opportunities and advances ’, on 16 November at 7AM PDT / 10AM EST / 3PM GMT / 4PM CET. Find out the answer to questions such as: Where is the opportunity in the cancer research market?

Research 52

Research Antibody Medicine RNA 52

Scienmag

MAY 7, 2021

Credit: UPMC PITTSBURGH, May 7, 2021 – In a paper published today in Nature Communications, an international group of collaborators led by researchers at UPMC Children’s Hospital of Pittsburgh have identified a genetic cause of a rare neurological disorder marked by developmental delay and loss of coordination, or ataxia.

Genetics 95

Genetics Genetic Disease RNA Protein 95

pharmaphorum

MAY 14, 2021

Biogen has made a further push into RNA-based drug discovery via a collaboration with Envisagenics, which applies artificial intelligence RNA sequencing data to discover new drug targets and therapeutics. It’s not the first partnership for Biogen in the RNA splicing area.

RNA 59

RNA Licensing Licensing Genetics 59

The Pharma Data

MARCH 7, 2022

By combining CRISPR technology with a protein designed with artificial intelligence (AI), it is possible to awaken individual dormant genes by disabling the chemical “off switches” that silence them. Researchers from the University of Washington School of Medicine in Seattle describe this finding in the journal Cell Reports.

Protein 52

Protein Gene Genome Genomics 52

Drug Discovery World

OCTOBER 11, 2023

The DDW Turning Science into Business Summit, ‘Cancer research opportunities and advances ’ will feature an expert panel discussion on new drug discovery and development concepts and tools in cancer research. The post DDW Cancer Research Summit: Industry experts join the panel appeared first on Drug Discovery World (DDW).

Research 52

Research Antibody RNA Engineer 52

Pharmaceutical Technology

JULY 5, 2022

Researchers at the UNC School of Medicine have discovered that hepatitis A virus (HAV) replication needs particular interactions between the human protein ZCCHC14 and TENT4 poly(A) polymerases, a group of enzymes. In addition, the scientists later found that the HAV needs TENT4A/B for its replication.

Protein 130

Protein RNA Genome Genomics 130

Drug Discovery World

NOVEMBER 1, 2022

Researchers say they have successfully used a cell’s natural process for making proteins to ‘slide’ genetic instructions into a cell and produce critical proteins missing from those cells. . Credit: Alexei Bygrave, Johns Hopkins Medicine. Splicing-linked expression design. in their effectiveness. “We

Gene Expression 52

Gene Expression Gene Packaging Packaging 52

Pharmaceutical Technology

MAY 25, 2023

The technology platforms include the Life Edit gene editing platform, an RNA, cell, protein, vector engineering and induced pluripotent stem cells (iPSCs) platform. ElevateBio intends to use the funds to advance its genetic medicine current good manufacturing practice (cGMP) and process development business, BaseCamp.

Gene Therapy 243

Gene Therapy Gene Gene Editing Manufacturing 243

pharmaphorum

JANUARY 26, 2023

Both long- and short-read sequencing today is faster, more affordable, and highly accurate, providing researchers with deep insights to fuel research. Moreover, research has shown that genetic testing can reduce adverse reactions to drugs by nearly one third. Just one mutation can lead to a complete change in protein formation.

Genome 128

Genome Genomics Genome Project Genetics 128

Pharmaceutical Technology

FEBRUARY 3, 2023

Since HIV integrates with the DNA, eliminating the virus from the body is very difficult, explains David Montefiori, PhD, director of the Laboratory for AIDS Vaccine Research and Development at Duke University in Durham, North Carolina. But others in the research space are now testing out other concepts that have been largely theoretical.

Vaccination 293

Vaccination Vaccine Antibody Trials 293

Drug Discovery World

MARCH 21, 2023

In a step forward for genetic engineering and synthetic biology, US researchers have modified E coli bacteria to be immune to infection by all natural viruses tested so far. coli to make all their life-sustaining proteins from 61 sets of genetic building blocks, or codons, instead of the naturally occurring 64.

Engineer 52

Engineer Genetic Engineering Scientist Bacteria 52

Drug Discovery World

AUGUST 4, 2023

The pace of innovation in cancer drug discovery showed no signs of slowing this week, with several pretty momentous discoveries boosting research in the sector. News round-up for 31 July – 4 August by DDW Digital Content Editor Diana Spencer.

Drugs 52

Drugs RNA Gene Scientist 52

Roots Analysis

JANUARY 28, 2024

Pharmaceutical Research: Big data analytics can be applied in various areas of pharmaceutical research, including drug discovery and development, precision medicine , clinical trial optimization, pharmacovigilance and drug safety, supply chain optimization, and real-time monitoring and surveillance.

Big Data 40

Big Data Medicine Marketing Clinical Trials 40

Pharmaceutical Technology

APRIL 26, 2023

MiNA Therapeutics has entered into a research collaboration and option licensing agreement with BioMarin Pharmaceutical to speed up the development of therapeutic ribonucleic acid activation (RNAa) candidates to treat rare genetic diseases. The option licensing agreement is based on early-stage clinical results.

Development 130

Development Genetic Disease Genetics Gene Therapy 130

Drug Discovery World

MARCH 3, 2023

Professor Achim Aigner, Clinical Pharmacology in the Faculty of Medicine at Leipzig University, said “Due to their parallel, selective effects on multiple defined targets, miRNAs offer exceptional opportunities for the development of novel drugs that show enhanced efficacy while avoiding tumour cell resistance.

Development 52

Development RNA Drug Delivery Regulation 52

Drug Discovery World

OCTOBER 26, 2023

To enable Evotec’s precision medicine approach, we have been building technology platforms that allow PanOmics or multi-omics data generation at an industrialised scale. The technologies cover the whole range of biomolecules from genes to protein to metabolites. This article is sponsored by Evotec.

Drugs 52

Drugs Protein Genome Genomics 52

Drug Discovery World

SEPTEMBER 27, 2023

Founder Dr Moshe Szyf Founder shares the potential of harnessing precision medicine. Embarking on a new era of medicine The advent of genomics has ushered in the era of personalised medicine, enabling us to analyse the genetic makeup of individuals with unprecedented accuracy.

DNA 115

DNA Genetics Gene Medicine 115

Drug Discovery World

JANUARY 21, 2024

Inspired by the overall event theme of ‘Innovation at Every Turn’, the DDW track will present leading research and case studies from experts in academia, government agencies and the industry on how technology is innovating from bench to bedside, lab to patient. It is sponsored by Integra Biosciences and Hamamatsu Corporation.

Protein 52

Protein Vaccination Vaccine Development 52

Scienmag

NOVEMBER 18, 2020

— Research on a genetic heart disease has uncovered a new and unexpected mechanism for heart failure. This landmark discovery found a correlation between the clumping of RNA-binding proteins long linked to neurodegenerative disease ? ROCHESTER, Minn.

Genetics 40

Genetics RNA Protein Research 40

Delveinsight

AUGUST 26, 2021

Shape’s RNA editing technologies can modify the RNA sequence, which makes the body’s protein building blocks. This system is designed to deliver RNA editing technology or other payloads directly to particular body areas, such as the nervous system or muscle. and Leila Zegna, director of the Kabuki Syndrome Foundation.

Vaccination 98

Vaccination Vaccine Gene Therapy RNA 98

Drug Discovery World

AUGUST 16, 2023

The study, by researchers at The Institute of Cancer Research, London, shows that certain characteristics within patients’ primary tumours can predict how they will respond to different treatments after their tumours have spread around the body.

Genetics 52

Genetics Gene Hormones RNA 52

The Pharma Data

JUNE 7, 2023

Acuitas’ LNP technology will support Bayer’s in vivo gene editing and protein replacement programs by specifically delivering RNA payloads to the desired target organ, the liver. a biotechnology company specializing in the development of lipid nanoparticle (LNP) delivery systems for molecular therapeutics.

Gene Therapy 40

Gene Therapy Gene Gene Editing In-Vivo 40

Pharmaceutical Technology

DECEMBER 9, 2022

M&A – Commended PRODUCT LAUNCHES – Commended RESEARCH AND DEVELOPMENT – Commende d. Solvias is a Swiss-based pharmaceutical company focused on contract research, development and manufacturing. Pharmaceutical Technology Excellence Rankings – The Verdict.

Development 130

Development Manufacturing Production Vaccination 130

pharmaphorum

OCTOBER 31, 2022

VRG50635 was discovered using Verge’s AI-powered discovery platform ConVERGE which maps out the biological underpinnings of diseases using data on DNA, RNA and protein profiles to identify new targets and drug that can interact with them.

Genome 135

Genome Genomics Drugs RNA 135

pharmaphorum

AUGUST 18, 2020

The Corona Accelerated R&D in Europe (CARE) has been hastily set up by Europe’s Innovative Medicines Initiative (IMI), focusing on tackling the pandemic that has wreaked so much havoc across the world this year. The consortium aims to rapidly develop drugs to fight SARS-CoV-2 and find virus neutralising antibodies.

Protein 112

Protein Pharma Companies RNA Drugs 112

Drug Discovery World

JANUARY 26, 2023

The molecule, known as lissodendoric acid A, appears to counteract other molecules that can damage DNA, RNA and proteins and even destroy whole cells. We hope others will also be able to use cyclic allenes to make new medicines.” Image shows: Lissodendoryx florida (PIBOC O47-283) by spongiologist Vladimir B Krasokhin.

RNA 52

RNA Medicine DNA Protein 52

The Pharma Data

MARCH 8, 2022

Researchers led by Prof. The virus carries the information to produce a series of proteins, capable of inhibiting antiviral recognition systems of the infected cell. Actually, these systems could identify viral genetic material (here: Ribonucleic acids/RNAs) and sound the alarm. Camouflage protects virus from immune system.

Immune Response 52

Immune Response RNA Protein Genetics 52

Drug Discovery World

JANUARY 23, 2023

Researchers have discovered a clinical drug that sensitises glioblastoma (GBM) cells to radiotherapy and could replace the current standard of care. Armed with this understanding, the researchers further demonstrated that the genetic inhibition of DGAT1 suppresses radioresistance.

FDA Approval 52

FDA Approval Drugs In-Vivo In-Vitro 52

The Pharma Data

FEBRUARY 25, 2022

Several FDA-approved drugs – including for type 2 diabetes, hepatitis C and HIV – significantly reduce the ability of the Delta variant of SARS-CoV-2 to replicate in human cells, according to new research led by scientists at Penn State. ” The findings published today (Feb. 25) in the journal Communications Biology. .

FDA Approval 52

FDA Approval Drugs Protein In-Vitro 52

pharmaphorum

NOVEMBER 10, 2021

Not so, says the NIH, which argues that three of its scientists – John Mascola, Barney Graham and Kizzmekia Corbett – should be named as co-inventors of the messenger RNA sequence coding for the SARS-CoV-2 spike protein that is the main component of Moderna’s mRNA-1273 shot. The patent has been filed but not yet awarded.

Vaccination 102

Vaccination Vaccine Scientist Protein 102

Drug Discovery World

JANUARY 23, 2023

Following the release of Clarivate’s report ‘RNA Technology Companies to Watch’, DDW’s Diana Spencer speaks to Strand Therapeutics’ Jacob Becraft and HAYA Therapeutics’ Samir Ounzain to find out how this technology could revolutionise disease treatment.

RNA 98

RNA Genome Genomics Engineer 98

Drug Discovery World

APRIL 6, 2023

Ahead of attending the American Association for Cancer Research (AACR) annual meeting from 14-19 April, 2023 at the Orange County Convention Center in Orlando, Florida, DDW’s Megan Thomas outlines what to expect from the event. Programme highlights The topic tracks include everything from clinical trials, drug development, immunology and bioinformatics, (..)

Protein 52

Protein Clinical Trials Clinical Trials Antibody 52

Delveinsight

JULY 29, 2021

The acquisition of Teneobio will bolster their ability to develop innovative medicines to treat patients with serious illnesses and to bring to market best-in-class products, particularly concerning multispecific and bispecific medicines directed against targets in a broad range of diseases across their core therapeutic areas, as said by David M.

Drugs 98

Drugs Protein Life Science Trials 98

XTalks

AUGUST 5, 2020

In recent webinars by Genuity Science, formerly known as WuXi NextCODE, experts from the biotech and pharma industries spoke about leveraging the power of single cell RNA sequencing platforms and solutions in conjunction with machine learning technologies such as AI in cell biology and disease research.

Gene Expression 112

Gene Expression Development RNA Drugs 112

XTalks

AUGUST 12, 2020

Despite the effectiveness of anti-retroviral therapy (ART) in significantly improving health, quality of life and reducing mortality among HIV-positive individuals, new research shows that persistent infections may be due to the ability of the virus to take refuge in distinct subsets of immune T cells.

RNA 52

RNA Protein DNA In-Vivo 52